WRN Antibody

What is WRN protein and what are its key structural domains?

WRN is a 1432 amino acid protein with a calculated molecular weight of 162 kDa that functions as an ATP-dependent helicase. Also known as RECQ3 or RecQ protein-like 2, it contains several functional domains that are critical for its biological activities. The protein contains one HRDC (Helicase and RNase D C-terminal) domain, one helicase C-terminal domain, one helicase ATP-binding domain, and a 3'-5' exonuclease domain .

WRN belongs to the RecQ helicase family and possesses both helicase and exonuclease activities. It plays a central role in repairing methylation-induced DNA damage and has helicase activity necessary to prevent dramatic telomere loss during DNA replication. Notably, WRN gene mutations are associated with Werner syndrome (a premature aging disease) and colorectal cancer .

What applications are WRN antibodies typically used for?

WRN antibodies are versatile research tools employed in multiple applications:

• Western Blot (WB): The recommended dilution range is typically 1:200-1:1000, though this should be optimized for specific sample types . Western blotting is the most common technique for detecting WRN protein expression levels.

• Immunoprecipitation (IP): Used to isolate WRN protein complexes and identify protein-protein interactions with WRN. For example, FLAG-tagged WRN can be immunoprecipitated using anti-FLAG monoclonal antibody M2 beads .

• Immunocytochemical staining: Used to determine the subcellular localization of WRN protein, which has been shown to be primarily in the nucleoplasm rather than the nucleolus .

• ELISA: For quantitative detection of WRN protein levels in various samples .

• Detection of post-translational modifications: Specialized applications include detecting acetylated WRN using anti-acetylated lysine antibodies following immunoprecipitation of WRN protein .

Each application requires specific optimization conditions, and antibody performance may vary depending on the experimental context and sample type.

What is the subcellular localization of WRN protein?

Immunocytochemical staining studies have definitively shown that WRN protein is primarily localized in the nucleoplasm rather than in the nucleolus. This finding has been confirmed using both mouse monoclonal antibodies specific to human WRN helicase and rat monoclonal antibodies specific to the mouse homologue of human WRN helicase .

Interestingly, while WRN exhibits nucleoplasmic staining in interphase cells, it does not appear to associate with condensed chromatin during metaphase. This suggests that WRN helicases may exist in a soluble form or bound to unfolded chromatin structures . This localization pattern is consistent with WRN's roles in DNA replication, recombination, and repair processes.

The nuclear localization reflects WRN's function in maintaining genomic stability, as it needs to be in close proximity to DNA to perform its helicase and exonuclease activities. This subcellular distribution information is crucial for designing experiments to study WRN function and for interpreting results of immunolocalization studies.

How does WRN expression vary across different cell types?

WRN protein expression shows significant variation across different cell types, with particularly notable differences between normal and transformed cells:

• Transformed cells and tumor cell lines consistently show higher WRN expression levels compared to normal cells . This suggests WRN may play an important role in supporting the high proliferation rates characteristic of cancer cells.

• Expression level hierarchy: Immunoblot analysis has revealed that immortal EBV-transformed B cells exhibit the highest WRN expression, followed by mortal EBV-transformed B cells, with untransformed B cells in peripheral blood showing the lowest expression levels .

• Specific cell lines known to express detectable levels of WRN include MCF-7 (breast cancer) and HEK-293 (embryonic kidney) cells .

• WRN protein is not detected in cells from Werner syndrome patients with defined mutations in the WRN gene, making these cells useful negative controls for antibody validation .

This differential expression pattern has important implications for cancer biology and may partly explain why WRN gene mutations are associated with both premature aging and cancer predisposition. Researchers should consider these expression differences when selecting appropriate cell models for studying WRN function.

What is the recommended protocol for WRN antibody use in Western blotting?

For optimal Western blot results with WRN antibody, follow this methodological approach:

• Sample preparation:

  • Lyse cells in an appropriate buffer containing protease inhibitors

  • For studies involving post-translational modifications, include specific inhibitors (e.g., 10 μM TSA and 5 mM nicotinamide for acetylation studies)

• Protein separation:

  • Use 8% SDS-PAGE gels for optimal separation due to WRN's large size (162-180 kDa)

• Transfer:

  • Transfer proteins to PVDF membrane (e.g., Immobilon-P)

  • Consider extended transfer times for high molecular weight proteins

• Blocking:

  • Block membrane with TBS (20 mM Tris-HCl, 150 mM NaCl, pH 7.5) containing 5% (wt/vol) skim milk for 1 hour

• Primary antibody incubation:

  • Dilute WRN antibody 1:200-1:1000 in blocking buffer

  • Incubate overnight at 4°C

• Washing and secondary antibody:

  • Wash thoroughly with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody (e.g., anti-mouse IgG-HRP)

• Detection:

  • Develop using an enhanced chemiluminescence (ECL) system

It's crucial to titrate the antibody in each testing system to obtain optimal results, as the optimal dilution may be sample-dependent . When analyzing results, expect to observe WRN at approximately 162-180 kDa.

How can I detect post-translational modifications of WRN protein?

Detection of WRN post-translational modifications, particularly acetylation, requires specific methodological considerations:

• For WRN acetylation detection:

  • Transfect cells (e.g., HEK293) with FLAG-WRN alone or with a CBP-containing plasmid DNA to enhance acetylation

  • Harvest cells 36 hours post-transfection

  • Include deacetylase inhibitors (10 μM TSA and 5 mM nicotinamide) in lysis buffer

  • Immunoprecipitate using anti-FLAG beads if using tagged WRN

  • Perform Western blotting with anti-acetylated lysine antibodies to detect acetylated WRN

  • Re-probe with anti-WRN antibodies to confirm total WRN levels

• For studying acetylation effects on WRN function:

  • Compare wild-type WRN with acetylation site mutants (e.g., WRN-6KR)

  • Perform functional assays such as helicase or exonuclease activity assays

  • Assess protein stability through cycloheximide chase experiments

• For other modifications (phosphorylation, ubiquitination):

  • Use modification-specific antibodies after immunoprecipitation

  • Include appropriate inhibitors in lysis buffers (phosphatase inhibitors for phosphorylation studies)

  • Consider mass spectrometry for unbiased identification of modification sites

These approaches allow researchers to investigate how post-translational modifications regulate WRN function, stability, and interactions, providing insights into WRN's roles in various cellular processes including DNA repair and replication.

What are the best methods for assessing WRN helicase activity?

To assess WRN helicase activity in vitro, follow this systematic methodological approach:

• Substrate preparation:

  • Generate a DNA substrate with a partial duplex structure

  • Example: Radiolabel a 62-mer oligonucleotide (5′-CACTGACTCCAGGAACTGGAGGATGCCTAGGTGGCCAGCTGCCGTCCAG-ACTCAGAGGAGTG-3′) with [γ-32P]-ATP

  • Anneal with unlabeled, partially complementary 52-mer oligonucleotide

  • Purify the annealed substrate by gel electrophoresis

• WRN protein preparation:

  • Purify FLAG-tagged WRN (wild-type or mutants) using immunoprecipitation

  • Alternatively, use recombinant WRN expressed in insect cells or E. coli

• Helicase reaction:

  • Incubate purified WRN with DNA substrate for 30 min at 37°C in WRN reaction buffer containing:

    • 40 mM Tris-HCl, pH 8.0

    • 1 mM MgCl₂

    • 250 μM ATP

    • 0.1% NP-40

    • 100 μg/ml BSA

    • 5 mM DTT

• Analysis:

  • Terminate reactions with Proteinase K, SDS, and EDTA

  • Resolve products on native polyacrylamide (6%) gel

  • Visualize by phosphorimaging

• Controls and validation:

  • Include catalytically inactive WRN mutants (e.g., K577M for helicase-dead)

  • Test WRN helicase inhibitors like NSC19630 as pharmacological controls

  • Compare wild-type WRN with post-translationally modified forms

This assay can be adapted to investigate factors affecting WRN helicase activity, including protein interactions, post-translational modifications, and small molecule inhibitors, providing valuable insights into WRN function in DNA metabolism.

What controls should be included when working with WRN antibodies?

When working with WRN antibodies, proper controls are essential for result validation:

• Positive controls:

  • Cell lines with known WRN expression (MCF-7, HEK-293 cells)

  • Recombinant WRN protein or fragments

  • Include molecular weight markers to confirm correct size (162-180 kDa)

• Negative controls:

  • WRN-knockout or WRN-depleted cells

  • Cells from Werner syndrome patients with defined WRN mutations

  • Pre-immune serum (for polyclonal antibodies) or isotype control (for monoclonal antibodies)

• Specificity controls:

  • Peptide competition assay: Pre-incubation of antibody with immunizing peptide

  • Secondary antibody only: Omit primary antibody to assess non-specific binding

  • For immunofluorescence, include DAPI staining to verify nuclear localization

• Loading and procedural controls:

  • For Western blots, include housekeeping proteins (e.g., β-actin)

  • For immunoprecipitation, perform IgG control immunoprecipitation

  • For functional studies, include both wild-type and mutant WRN proteins

• Cell type controls:

  • Compare transformed cells (high WRN expression) with normal cells (lower expression)

  • Use cell lines from different tissues to account for tissue-specific expression patterns

Implementing these controls will help validate antibody specificity, ensure proper experimental conditions, and support the reliability of findings when studying WRN protein in various research applications.

How does WRN depletion affect cell proliferation and DNA damage?

WRN depletion has significant and sometimes paradoxical effects on cell proliferation and DNA damage, which vary by cell type:

• Effects on cell proliferation:

  • Enhanced basal cell proliferation in epithelial cells (N/Tert-1) lacking WRN expression

  • WRN-depleted cells show increased resistance to WRN helicase inhibitors (NSC19630), suggesting cellular adaptation to WRN loss

  • In HPV16-containing cells, WRN depletion enhances basal cell proliferation

• Effects on DNA damage:

  • Increased DNA damage in cells without WRN expression

  • In N/Tert-1 cells, WRN depletion results in elevated DNA damage markers

  • In HPV16-containing epithelium, WRN depletion leads to increased DNA damage throughout the cell layers

• Effects on differentiation:

  • Thickening of the differentiated epithelium in WRN-depleted cells

  • WRN expression is required for normal epithelial cell differentiation

These findings reveal WRN's complex role as a tumor suppressor that controls cell proliferation, maintains genomic stability, and regulates differentiation. The enhanced proliferation observed in WRN-depleted cells likely comes at the cost of increased DNA damage and genomic instability, potentially contributing to the cancer predisposition observed in Werner syndrome patients.

What is the relationship between WRN and viral life cycles?

WRN plays a crucial role in regulating viral life cycles, particularly for human papillomavirus 16 (HPV16):

• WRN as a restriction factor:

  • WRN functions as a restriction factor for HPV16, controlling viral DNA replication throughout the epithelium

  • WRN depletion leads to increased viral DNA replication in HPV16-containing cells

  • WRN controls both the levels and fidelity of HPV16 E1-E2 DNA replication

• Effects on HPV16-infected cells:

  • In N/Tert-1+HPV16 cells, WRN depletion results in:

    • Enhanced basal cell proliferation

    • Increased DNA damage throughout the epithelium

    • Altered viral life cycle in differentiating keratinocytes

• Mechanism of restriction:

  • WRN likely controls viral replication through its helicase and/or exonuclease activities

  • WRN regulates the DNA damage response triggered by viral replication

  • The IC50 for WRN helicase inhibitor (NSC19630) is similar in N/Tert-1+HPV16 and N/Tert-1+HPV16-WRN cells, suggesting that HPV16 may attenuate WRN function

This research demonstrates a novel role for WRN beyond its established functions in cellular DNA metabolism. WRN appears to be part of the host defense against viral pathogens, protecting cells from virus-induced DNA damage and controlling viral replication. Understanding this relationship could lead to new approaches for treating HPV infections.

How do post-translational modifications regulate WRN function?

Post-translational modifications, particularly acetylation, play crucial roles in regulating WRN function:

• WRN acetylation:

  • WRN contains multiple lysine residues that can be acetylated

  • Acetylation is mediated by acetyltransferases such as CBP

  • Acetylation inhibits ubiquitin-mediated degradation of WRN protein, increasing its stability

  • Deacetylation, mediated by proteins such as SIRT1, may promote WRN degradation

• Experimental approaches:

  • Transfection with CBP-containing plasmid enhances WRN acetylation

  • Detection uses anti-acetylated lysine antibodies following immunoprecipitation

  • SIRT1 siRNA can be used to study the effects of enhanced WRN acetylation

• Functional consequences:

  • Acetylation status affects WRN's biochemical activities (helicase and exonuclease functions)

  • Regulates WRN's involvement in DNA replication, recombination, and repair

  • Influences WRN's protein-protein interactions and subcellular localization

• Other modifications:

  • Phosphorylation affects WRN activity and localization during cell cycle and DNA damage

  • Ubiquitination regulates WRN protein turnover

  • Sumoylation may affect WRN's biochemical activities

These post-translational modifications represent important regulatory mechanisms for WRN function, linking its activity to various cellular processes and stress responses. Understanding the interplay between different modifications provides insights into WRN's roles in aging, cancer, and genome maintenance.

What proteins interact with WRN and what are the functional implications?

WRN engages in numerous protein-protein interactions that regulate its functions in DNA metabolism:

• Proteome-wide identification:

  • Proteomics studies have identified 49 proteins predicted or confirmed to interact with WRN

  • 21 of these proteins were validated through multiple approaches

• Key interaction partners include:

  • DNA replication factors (PCNA, RPA, topoisomerases)

  • DNA repair proteins (Ku70/80, MRN complex, PARP1)

  • Telomere maintenance factors (TRF1, TRF2, POT1)

  • Transcription factors and chromatin remodelers (p53, histones)

  • Post-translational modifiers (CBP, SIRT1)

• Functional implications:

  • Localization of WRN to specific DNA structures or damage sites

  • Regulation of WRN enzymatic activities

  • Integration of WRN into various DNA metabolism pathways

  • Coordination of cellular responses to DNA damage or replication stress

• Methods for studying interactions:

  • Immunoprecipitation followed by Western blotting or mass spectrometry

  • Yeast two-hybrid screening

  • Proximity ligation assays

  • Domain mapping using truncated proteins

Understanding these interactions provides insights into the multifaceted roles of WRN in genome maintenance and helps explain the complex phenotypes associated with Werner syndrome, including premature aging and cancer predisposition. These interactions also suggest potential therapeutic targets for diseases associated with WRN dysfunction.

Why might I not detect WRN protein in my samples?

Failure to detect WRN protein can result from multiple biological and technical factors:

• Biological considerations:

  • Low endogenous expression in your cell type (normal cells typically express less WRN than transformed cells)

  • WRN mutations or deletions in your sample (e.g., cells from Werner syndrome patients)

  • Cell cycle-dependent expression

  • Degradation due to cellular stress or specific treatments

• Sample preparation issues:

  • Insufficient protein extraction (WRN is nuclear and may require specialized extraction)

  • Protein degradation during preparation (ensure fresh protease inhibitors)

  • Incomplete cell lysis (optimize lysis conditions for nuclear proteins)

  • Sample overheating during processing

• Western blot optimization needs:

  • Use 8% or lower percentage gels for better resolution of high molecular weight proteins (162-180 kDa)

  • Optimize transfer conditions for large proteins

  • Ensure appropriate blocking (5% milk in TBS)

  • Verify antibody concentration (try 1:200-1:1000 dilution range)

• Antibody-specific factors:

  • Epitope masking due to protein modifications or interactions

  • Antibody specificity for certain species or isoforms

  • Storage conditions affecting antibody quality

To troubleshoot, run positive controls (e.g., HEK-293 or MCF-7 cells) , optimize nuclear protein extraction, and validate your antibody with multiple approaches.

How can I validate the specificity of my WRN antibody?

Validating WRN antibody specificity requires multiple complementary approaches:

• Genetic validation:

  • Test antibody on WRN knockout or knockdown cells

  • Compare staining in cells from Werner syndrome patients vs. normal cells

  • Use cells expressing tagged WRN (e.g., FLAG-WRN) to confirm co-localization

• Biochemical validation:

  • Peptide competition assay: Pre-incubate antibody with immunizing peptide

  • Use multiple antibodies targeting different WRN epitopes

  • Perform immunodepletion experiments

  • Verify detection at the correct molecular weight (162-180 kDa)

• Functional validation:

  • Correlate antibody staining with functional readouts

  • Test if immunoprecipitated protein exhibits expected enzymatic activities

  • Use WRN helicase inhibitors (e.g., NSC19630) to confirm specificity of functional assays

• Expression pattern analysis:

  • Verify nuclear localization

  • Confirm expected expression patterns across cell types (higher in transformed cells)

  • Check for expected changes with treatments known to affect WRN

• Cross-reactivity assessment:

  • Test against related RecQ helicases

  • Perform mass spectrometry on immunoprecipitated proteins

Thorough validation ensures experimental reliability and provides crucial information for optimizing protocols to study WRN protein in various research applications.

What is the relationship between WRN expression levels and cell transformation?

WRN expression shows a striking correlation with cellular transformation status:

• Expression level differences:

  • Higher levels of WRN helicase are consistently observed in transformed cells and tumor cells compared to normal cells

  • Expression hierarchy: immortal EBV-transformed B cells > mortal EBV-transformed B cells > untransformed B cells

  • Various tumor cell lines show elevated WRN expression

• Detection methods:

  • Quantitative immunoblot analysis with specific WRN antibodies reveals these differences

  • Endogenous WRN helicase (approximately 180 kD) can be detected in cultured cell lines

• Functional implications:

  • Higher WRN levels may support increased proliferation in cancer cells

  • May help cancer cells cope with replication stress

  • Could contribute to genomic instability characteristic of cancer cells

  • Suggests WRN as a potential therapeutic target in cancer

• Research applications:

  • WRN expression levels could potentially serve as a biomarker

  • Differential sensitivity to WRN inhibitors between normal and cancer cells

  • Understanding how transformation affects WRN regulation

This differential expression pattern suggests that WRN function may be particularly important in rapidly dividing transformed cells, potentially explaining why WRN gene mutations are associated with both premature aging and cancer predisposition.

What are the recommended storage conditions for WRN antibodies?

Proper storage of WRN antibodies is critical for maintaining their performance and specificity:

• General storage recommendations:

  • Store at -20°C for long-term preservation

  • Antibodies are typically stable for one year after shipment when stored properly

  • For small volumes (20μl), aliquoting is unnecessary for -20°C storage

  • Some preparations contain 0.1% BSA as a stabilizer

• Storage buffer composition:

  • WRN antibodies are typically stored in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

  • This formulation helps maintain antibody stability during freeze-thaw cycles

• Best practices:

  • Minimize freeze-thaw cycles

  • When working with the antibody, keep on ice

  • Return to -20°C promptly after use

  • For repeated access, consider preparing small working aliquots

  • Follow manufacturer's specific recommendations for each antibody

• Signs of antibody deterioration:

  • Increased background in Western blots or immunostaining

  • Reduced signal intensity

  • Appearance of non-specific bands

  • Precipitate formation in the antibody solution

Following these storage recommendations will help ensure consistent performance and extend the useful life of WRN antibodies in research applications.

What are the most critical considerations for designing experiments with WRN antibodies?

When designing experiments using WRN antibodies, researchers should prioritize these critical considerations:

• Antibody selection and validation:

  • Verify antibody specificity using multiple approaches (knockout controls, Western blotting at correct molecular weight, etc.)

  • Consider using multiple antibodies targeting different epitopes for confirmation

  • Review the literature for antibody performance in your specific application

• Experimental controls:

  • Include positive controls (HEK-293, MCF-7 cells)

  • Use appropriate negative controls (WRN-depleted cells, Werner syndrome patient cells)

  • Include loading controls and procedural controls

• Cell type considerations:

  • Account for variable WRN expression across cell types (transformed vs. normal cells)

  • Consider cell cycle effects on WRN expression and localization

  • For primary cells, passage number may affect WRN levels

• Technical optimizations:

  • Use low percentage gels (8% or less) for Western blotting

  • Optimize antibody dilution for each application (1:200-1:1000 for Western blot)

  • Use nuclear extraction protocols for maximum yield

• Application-specific considerations:

  • For post-translational modification studies, include appropriate inhibitors

  • For interaction studies, consider crosslinking approaches

  • For functional studies, include activity assays to correlate expression with function

These considerations will help ensure robust, reproducible results when working with WRN antibodies across various research applications, from basic protein detection to complex functional studies investigating WRN's roles in genome maintenance, aging, and cancer.